Teaching note for product 9B06M070.

The founder chairman and managing director wants to make Biocon, Ltd. one of the top 10 biotech firms by 2015. The company has dealt in low-risk enzymes and generic drugs for many years. In order for the company to grow, the chairman believes that Biocon must enter the riskier business of drug discovery and development. Without making large investments into new capabilities, the company cannot become a top 10 biotech firm.

Teaching Note for product 9B05M045.

The inventor and founder of DEKA research was deciding whether to commercialize his latest invention, the Segway Human Transporter, a self-balancing, battery-operated scooter. The transporter was envisioned as an alternative mode of personal transportation in traffic-clogged urban environments. It also had potential application in developing countries with limited transportation infrastructure. With the versatility to carry riders on sidewalks, rough .....more

Teaching note for product 9B01M066.

A new biotechnology firm, Pharma Technologies, has developed a competing method for the treatment of erectile dysfunction which promises significant advantages over Pfizer's blockbuster drug, Viagra. With deep-pocketed pharmaceutical companies also pursuing product development efforts, the president of Pharma Technologies is charged with deciding how to leverage his company's superior proprietary technology into a viable product before the .....more

Teaching note for product 9B03M035.

In the (A) case, the co-chief executive officers are considering a variety of different business models for developing a public wireless LAN network for Internet service in major "hot spot" locations. The (B) case focuses on whether they should pursue a strategic partnership with a major telecommunication company, and under what conditions. The (C) case takes place nine months later, after a deal has been struck. Described is how the agreement .....more

BLES Biochemicals Inc. is a research and development company that specializes in natural surfactants. After many years of trying, the president has finally obtained approval for the company's only product, BLES. The product is used to help premature babies suffering from respiratory distress syndrome - without it, they could die. The company had been allowed to sell the product in advance of receiving the approval but with the news of receiving .....more

This is a supplement to BLES Biochemicals Inc. (A), product 9B03M026. The (A) case explores the growth options available to a new biotech company with a revolutionary drug for premature infants. There seems to be a significant potential for international growth. The (B) case takes place six months later when the president of the company obtains new data concerning market size projections, technological advances and competitor actions that require .....more